KLRA

Kailera Therapeutics, Inc. - Common stock (KLRA)

About Kailera Therapeutics, Inc. - Common stock (KLRA)

Kailera Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Its product candidate includes Ribupatide. The company was founded on May 08, 2024 and is headquartered in Waltham, MA.

Details

Daily high

$18.89

Daily low

$17.50

Price at open

$18.35

52 Week High

$28.23

52 Week Low

$16.00

Market cap

2.4B

Dividend yield

Volume

1.3M

Avg. volume

433,485

P/E ratio

Kailera Therapeutics, Inc. - Common stock News